Novavax NVAX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Novavax (NVAX) Business Model and Operations Summary
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Key Insights
Novavax (NVAX) Core Market Data and Business Metrics
Latest Closing Price
$6.73Market Cap
$1.03 BillionAverage Trade Volume
5,383,140 SharesTotal Outstanding Shares
161.97 Million SharesCEO
Mr. John Charles Jacobs M.B.A.Total Employees
1,992IPO Date
December 5, 1995SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
700 Quince Orchard Road, Gaithersburg, MD, 20878
Earnings Reports
Expected vs. Actual Quarterly Earnings-Per-Share & Revenue
Short Volume
Daily short volume activity identifies short-term trading pressure and potential price volatility
Short Interest
Short Interest
This information represents bi-monthly aggregated short interest data reported to the Financial Industry Regulatory Authority (FINRA) by broker-dealers.
Settlement Date: The date on which the short interest data is considered settled, typically based on exchange reporting schedules.
Short Interest: The total number of shares that have been sold short but have not yet been covered or closed out.
Avg Daily Volume: The average daily trading volume for the stock over the specified period, typically used to contextualize short interest.
Days To Cover: The estimated number of days it would take to cover all short positions based on average trading volume.
Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential
Revenue Breakdown
Distribution of revenue across unique business segments & geographies
Historical Stock Splits
| Execution Date | Split Amount |
|---|